新型SS18-POU5F1融合基因的软组织肉瘤的治疗反应：一例报告
Therapeutic Response of Soft Tissue Sarcoma With Novel SS18-POU5F1 Fusion: A Case Report.
作者信息
Liu Zengjun, Yuan Hongtu, Han Mingyong
机构信息
Tumor Research and Therapy Center, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
出版信息
Front Oncol. 2021 Jun 24;11:666946. doi: 10.3389/fonc.2021.666946. eCollection 2021.
A novel SS18-POU5F1 fusion gene was recently reported in soft tissue sarcoma occurring in three adolescent and young adult patients. Herein, we firstly reported the treatment response of SS18-POU5F1 sarcoma to immune checkpoint inhibitor, angiogenesis inhibitor, chemotherapy and radiotherapy. Our patient demonstrated no response to various systemic therapies including immune checkpoint inhibitor, angiogenesis inhibitor and chemotherapy. However, we noted that the SS18-POU5F1 sarcoma had a quick, robust but transient clinical response to radiotherapy. Further studies are needed to elucidate the mechanism underlying the different tumor response to radiotherapy and systemic therapy in this kind of tumor.
最近在三名青少年和年轻成年患者发生的软组织肉瘤中报道了一种新的SS18-POU5F1融合基因。在此，我们首次报道了SS18-POU5F1肉瘤对免疫检查点抑制剂、血管生成抑制剂、化疗和放疗的治疗反应。我们的患者对包括免疫检查点抑制剂、血管生成抑制剂和化疗在内的各种全身治疗均无反应。然而，我们注意到SS18-POU5F1肉瘤对放疗有快速、强烈但短暂的临床反应。需要进一步研究以阐明这类肿瘤对放疗和全身治疗不同肿瘤反应的潜在机制。
Zotero 插件